Articles
-
Dec 12, 2024 |
healio.com | Glenn Yiu |Anthony DeFino
You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. CHICAGO — In this Healio Video Perspective from Retina Subspecialty Day at the AAO meeting, Glenn C.
-
Aug 8, 2024 |
nature.com | Glenn Yiu
This is a preview of subscription content, access via your institution Access options Subscribe to this journalReceive 18 print issues and online access$259.00 per yearonly $14.39 per issueBuy this articlePurchase on Springer LinkInstant access to full article PDFPrices may be subject to local taxes which are calculated during checkout Ethics declarations The authors declare no competing interests.
-
Jan 10, 2024 |
octnews.org | Glenn Yiu
University of California at Davis Receives a 2024 NIH Grant for $659,117 for Soft drusen in rhesus macaques as a nonhuman primate model of early age-related macular degeneration. The principal investigator is Glenn Yiu. Below is a summary of the proposed study. Age-related macular degeneration (AMD) is the leading cause of vision loss in the elderly, but current treatments target advanced stages when interventions may be limited by irreversible cell loss.
-
Apr 20, 2023 |
jamanetwork.com | Michael Nguyen |Glenn Yiu
A 23-year-old healthy woman with a history of pathologic myopia presented for evaluation of retinal aneurysms. Her visual acuity was 20/30 OD and 20/40 OS, and her refractive error was −14 diopters and −15 diopters in the right and left eyes, respectively. Fundus examination revealed clusters of aneurysmal lesions and telangiectasias along the inferior and temporal midperiphery of both eyes (Figure, A), which demonstrated late leakage on ultra–widefield fluorescein angiography (Figure, B).
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →